Study Title
A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
Protocol ID
TiNT
Disease (Sub Disease)
Solid tumours (Other Solid Tumour)
Diagnosis Stage
Relapsed/ refractory
Location
NSW, QLD, VIC, WA, SA, NZ, TAS
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
Perth Children's Hospital
Queensland Children's Hospital
Monash Children's Hospital
Sydney Children's Hospital
John Hunter Children's Hospital
Royal Children's Hospital
Royal Hobart Hospital
Christchurch Hospital
Starship Hospital
Women's & Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Monash Children's Hospital
Sydney Children's Hospital
John Hunter Children's Hospital
Royal Children's Hospital
Royal Hobart Hospital
Christchurch Hospital
Starship Hospital
Women's & Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
3 Months to 25 Years
ANZCTR
ACTRN12620001229965
| Study Title | A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas |
|---|---|
| Protocol ID | TiNT |
| Disease (Sub Disease) | Solid tumours (Other Solid Tumour) |
| Diagnosis Stage | Relapsed/ refractory |
| Location | NSW / QLD / VIC / WA / SA / NZ / TAS |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group |
| Links | https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379244&isReview=true |
| Trial Status | Open |
| Trial Open Date | 01/03/2021 |
| Sites | The Children's Hospital at Westmead / Perth Children's Hospital / Queensland Children's Hospital / Monash Children's Hospital/ Sydney Children's Hospital / John Hunter Children's Hospital/ Royal Children's Hospital / Royal Hobart Hospital/ Christchurch Hospital / Starship Hospital/ Women's & Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 3 Months to 25 Years |
| ANZCTR | ACTRN12620001229965 |